1. Long-term treatment with fibrates and ursodeoxycholic acid in people with Primary Sclerosing Cholangitis is safe and associated with persistent clinical and biochemical improvement. (March 2023) Authors: Catanzaro, E.; Peviani, M.; Perin, N.; Bonaiuto, E.; Simionato, F.; Motta, R.; Gambato, M.; Floreani, A.; Cazzagon, N. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. People with autoimmune hepatitis and celiac disease have a milder liver disease course and a better chance of immunosuppressive treatment withdrawal. (March 2023) Authors: Pezzato, F.; D'Ovidio, E.; Perini, L.; Bonaiuto, E.; Rollo, P.; Catanzaro, E.; Peviani, M.; Russo, F.P.; D'Odorico, A.; Zingone, F.; Floreani, A.; Cazzagon, N. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Quality of life outcomes in people with Primary Biliary Cholangitis treated with obeticholic acid: results of a phase 4 real life observational trial. (March 2023) Authors: Rollo, P.; D'Ovidio, E.; Bonaiuto, E.; Perini, L.; Pezzato, F.; Peviani, M.; Simionato, F.; Russo, F.P.; Floreani, A.; Cazzagon, N. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗